These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 27528625)

  • 1. Androgen receptor signaling pathways as a target for breast cancer treatment.
    Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
    Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
    Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the androgen receptor in breast cancer.
    Chia K; O'Brien M; Brown M; Lim E
    Curr Oncol Rep; 2015 Feb; 17(2):4. PubMed ID: 25665553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the androgen receptor in triple-negative breast cancer.
    Rampurwala M; Wisinski KB; O'Regan R
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the androgen receptor in triple-negative breast cancer.
    Gucalp A; Traina TA
    Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.
    Christenson JL; Trepel JB; Ali HY; Lee S; Eisner JR; Baskin-Bey ES; Elias AD; Richer JK
    Horm Cancer; 2018 Apr; 9(2):82-94. PubMed ID: 29340907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consideration of breast cancer subtype in targeting the androgen receptor.
    Venema CM; Bense RD; Steenbruggen TG; Nienhuis HH; Qiu SQ; van Kruchten M; Brown M; Tamimi RM; Hospers GAP; Schröder CP; Fehrmann RSN; de Vries EGE
    Pharmacol Ther; 2019 Aug; 200():135-147. PubMed ID: 31077689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
    Kono M; Fujii T; Lim B; Karuturi MS; Tripathy D; Ueno NT
    JAMA Oncol; 2017 Sep; 3(9):1266-1273. PubMed ID: 28301631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of the Androgen Receptor Signaling in Breast Malignancies.
    Christopoulos PF; Vlachogiannis NI; Vogkou CT; Koutsilieris M
    Anticancer Res; 2017 Dec; 37(12):6533-6540. PubMed ID: 29187427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
    Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
    Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceritinib is a novel triple negative breast cancer therapeutic agent.
    Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
    Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.
    Nahleh Z
    Future Oncol; 2008 Feb; 4(1):15-21. PubMed ID: 18240997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
    Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
    J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Androgen Receptor: Is It a Promising Target?
    Gucalp A; Traina TA
    Ann Surg Oncol; 2017 Oct; 24(10):2876-2880. PubMed ID: 28766215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer.
    You CP; Leung MH; Tsang WC; Khoo US; Tsoi H
    Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical signaling pathways of triple negative and triple positive breast cancers: What is new?
    Elsers DA; Masoud EM; Kamel NAMH; Ahmed AM
    Ann Diagn Pathol; 2021 Dec; 55():151831. PubMed ID: 34634762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
    Sharifi MN; O'Regan RM; Wisinski KB
    Clin Breast Cancer; 2023 Dec; 23(8):813-824. PubMed ID: 37419745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.